Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
15 Dec 2017
Change (% chg)

$-0.02 (-2.41%)
Prev Close
$0.83
Open
$0.84
Day's High
$0.88
Day's Low
$0.80
Volume
64,741
Avg. Vol
180,186
52-wk High
$5.25
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing.  Full Article

Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer.Jeffrey Bacha, cofounder of Co, will continue in role as president and in newly created position of chief operating officer​.Zarrabian and Bacha will continue to serve on company's board of directors​.  Full Article

DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals Inc <<>> CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing.  Full Article

DelMar Pharmaceuticals wins approval for listing on NASDAQ
Monday, 11 Jul 2016 

Delmar Pharmaceuticals Inc : Delmar pharmaceuticals announces approval for listing on nasdaq .Delmar pharmaceuticals says stock will begin trading on nasdaq capital market at opening of trading on tuesday, july 12, 2016 under ticker symbol dmpi.  Full Article

Delmar Pharma presents data from clinical trial of cancer treatment
Monday, 6 Jun 2016 

Delmar Pharmaceuticals Inc :Delmar pharmaceuticals presents phase I/II GBM clinical trial data and outlines future clinical development plans at ASCO 2016 annual meeting.  Full Article

DelMar Pharmaceuticals reports Q3 loss of $0.03 per share
Friday, 13 May 2016 

Delmar Pharmaceuticals Inc : DelMar Pharmaceuticals announces third quarter fiscal year 2016 financial results and corporate update . Q3 loss per share $0.03 .Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage: